PITTSBURGH–(BUSINESS WIRE)–

Met 30 jaar ervaring in de industrie zal Kreston de wereldwijde commercialisering en bedrijfsontwikkelingsfuncties van Knopp leiden tot de ontwikkeling van klinische ontwikkeling in een laat stadium

Knopp Biosciences LLC, een particulier bedrijf van de medicijnontdekking en ontwikkeling concentreerde zich bij het leveren van doorbraakbehandelingen voor ontstekings en neurologische ziekten van hoge unmet behoefte, kondigde vandaag de benoeming van het farmaceutische de industrieveteraanteken Kreston als zijn Belangrijkste Commerciële Medewerker aan. Kreston heeft meer dan 30 jaar ervaring met globale farmaceutische bedrijven die alle fasen van introductie op de markt overspannen.

Dit persbericht bevat multimedia. Bekijk het volledige persbericht hier: https://www.businesswire.com/news/home/20181206005127/en/

Knopp Biosciences Appoints Mark Kreston as Chief Commercial Officer

PITTSBURGH–(BUSINESS WIRE)–

30-year Industry Veteran Will Lead Knopp’s Global Commercialization, Business Development Functions as Company Advances Lead Asset into Late Stage Clinical Development

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today announced the appointment of pharmaceutical industry veteran Mark Kreston as its Chief Commercial Officer. Kreston has more than 30 years of experience with global pharmaceutical companies spanning all phases of commercialization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181206005127/en/

In his new role, Kreston will establish and execute global commercialization strategies and plans across the Knopp enterprise, with a particular focus on the Company’s lead program, dexpramipexole, an investigational drug candidate poised to enter Phase 3 trials in hypereosinophilic syndrome and Phase 2 trials in eosinophilic asthma. He will also be responsible for leading Knopp’s corporate strategy and business development activities, and will play a key role in the Company’s capital strategy.

“We are thrilled to welcome Mark to the Knopp team at this pivotal moment in our corporate development,” said Michael Bozik, M.D., Chief Executive Officer of Knopp. “His track record of launching major pharmaceutical products, including several blockbuster brands in the immunology sector, and his success in marketing oral products for conditions dominated by established biologics, will be invaluable as we advance dexpramipexole as a potential new treatment for eosinophil-associated diseases.”

Prior to joining Knopp, Kreston was corporate VP of Global Marketing, Inflammation & Immunology at Celgene, where he led the launch of Otezla for psoriasis. Before that, he served as worldwide VP of Global Marketing, Immunology at Johnson & Johnson, where he helped engineer global expansion of the company’s immunology business for Remicade and Stelara. Earlier, at Bristol-Myers Squibb, he was worldwide VP of Global Marketing, Immunology, responsible for launching Orencia for rheumatoid arthritis, and served as President of Consumer Medicines. Early in his career, he was product manager for Tylenol and Pepcid at McNeil Consumer Healthcare. Kreston holds a bachelor’s degree from the University of Pennsylvania and an MBA from the Cornell Johnson Graduate School of Management.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. Please visit www.knoppbio.com.

Forward Looking Statement

This press release contains “forward-looking statements,” including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp’s actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp’s pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181206005127/en/

Contacts

ICR Healthcare
Media:
James Heins
Tel: +1 203 682 8251
Email: James.Heins@icrinc.com